Patients with COPD taking ivacaftor for 12 weeks showed no significant changes in CFTR activity or mucociliary clearance, and lung function did not improve. Ivacaftor was safe and well tolerated but ...

TURIN, Italy I October 30, 2024 I Kither Biotech, a clinical-stage biotech company focused on innovative therapies for respiratory diseases, today announced ...